Peter D. Smith - Concepedia

Author

Peter D. Smith

Also Known As

P. D. SMITH, P. D. Smith, P. Smith, P.D. Smith, Peter D Smith, Peter D. Smith, Peter Smith, Smith, P., Smith, P.D., Smith, Peter D.

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Poland)AstraZeneca (Sweden)AstraZeneca (Brazil)Oxford Research Group

About

Peter D. Smith is an author at AstraZeneca (United Kingdom) specializing in pharmacology, natural sciences, and organic chemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Natural Sciences	9	9	756
2	Medicine	8	8	1K
3	Biochemistry	7	7	689
4	Engineering	5	5	92
5	Biology	1	1	43

Peter D. Smith

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor M. Raymond V. Finlay, Mark J. Anderton, Susan Ashton, Journal of Medicinal Chemistry GeneticsPathologyClinical CandidateTumor BiologyT790m Resistance Mutations	2014	590
Asymmetric routes to substituted piperidines Patrick D. Bailey, Paula A. Millwood, Peter D. Smith Chemical Communications Combinatorial ChemistryBioorganic ChemistryChiral PoolBiochemistryAsymmetric Routes	1998	328
Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) Richard A. Ward, Mark J. Anderton, Susan Ashton, Journal of Medicinal Chemistry Covalent InhibitorsDrug TargetThiol ReactivityTyrosine KinaseMolecular Biology	2013	257
Exploiting a fast neutron mutant genetic resource in Pisum sativum (pea) for functional genomics Claire Domoney, M. R. Knox, Carol Moreau, Functional Plant Biology Plant GeneticsGeneticsMolecular GeneticsGenomicsFast Neutron	2013	43
Tetrahydroisoquinoline Phenols: Selective Estrogen Receptor Downregulator Antagonists with Oral Bioavailability in Rat James S. Scott, Andrew Bailey, Robert D. M. Davies, ACS Medicinal Chemistry Letters Medicinal ChemistryOral BioavailabilityTetrahydroisoquinoline PhenolsPendant Aryl RingHormonal Contraceptive	2015	42
Catalytic direct amidations in <i>tert</i> -butyl acetate using B(OCH <sub>2</sub> CF <sub>3</sub> ) <sub>3</sub> Charlotte E. Coomber, Víctor Laserna, Liam Martin, Organic & Biomolecular Chemistry	2019	38
Silver-Free Palladium-Catalyzed C(sp<sup>3</sup>)–H Arylation of Saturated Bicyclic Amine Scaffolds Charlotte E. Coomber, Laure Benhamou, Dejan-Krešimir Buč̌ar, The Journal of Organic Chemistry	2017	37
Discovery of a Thiadiazole–Pyridazine-Based Allosteric Glutaminase 1 Inhibitor Series That Demonstrates Oral Bioavailability and Activity in Tumor Xenograft Models M. Raymond V. Finlay, Mark J. Anderton, Andrew Bailey, Journal of Medicinal Chemistry Oral BioavailabilityPharmacotherapyGls1 Inhibitor Bis-2-Pharmaceutical ChemistryMedicinal Chemistry	2019	29
Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: Synthesis and structure–activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors Laurent Hennequin, Peter Ballard, F. Tom Boyle, Bioorganic & Medicinal Chemistry Letters Structure–activity RelationshipMedicinal ChemistryBiochemistryNatural SciencesMedicine	2006	26
Enantioselective Synthesis of Atropisomeric Biaryls using Biaryl 2,5‐Diphenylphospholanes as Ligands for Palladium‐Catalysed Suzuki‐Miyaura Reactions Liam Byrne, Christian Sköld, Per‐Ola Norrby, Advanced Synthesis & Catalysis Biaryl 2,5‐DiphenylphospholanesEngineeringNatural SciencesDiversity-oriented SynthesisExemplary Phospholanes	2020	24

Page 1